Author

admin

Browsing

Investor Insight Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to inflammatory heart disease. The company’s 2025–2026 catalysts – MAVERIC Phase III enrollment progress, full ARCHER data, and CRD-38 clinical initiation – are key value drivers in…

In this video, Mary Ellen spotlights the areas driving market momentum following Taiwan Semiconductor’s record-breaking earnings report. She analyzes continued strength in semiconductors, utilities, industrials, and AI-driven sectors, plus highlights new leadership in robotics and innovation-focused ETFs like ARK. From there, Mary Ellen breaks down weakness in health care and…

Highlights: The latest drill results build on Bo_RC_14/25 drill hole (previously released as 12.0 metres @ 4.27% WO₃ from 252.0 metres, incl. 6.0 metres @ 8.39% WO₃ from 252.0 metres) and collectively suggests a larger and higher-grade Breccia complex than previously modeled. Bo_RC_17/25 results included 100.0 metres @ 0.21% WO₃…

Brings Company’s Total Claims to 491 in Area Housing the Only Rare Earths Producing Mine in U.S. Move Expands Locksley’s Exploration Pipeline Across Antimony, Rare Earths Elements and Polymetallic Prospects Locksley Resources Limited (ASX: LKY,OTC:LKYRF; OTCQB: LKYRF), announced it has significantly expanded its strategic footprint within the Mojave Critical Minerals…